XON:NAS (USA) Also trade in: Germany

Intrexon Corp

$ 4.11 -0.33 (-7.43%)
Volume: 20,775,552 Avg Vol (1m): 2,587,371
Market Cap $: 660.13 Mil Enterprise Value $: 665.42 Mil
P/E (TTM): 0.00 P/B: 1.47
Earnings Power Value -16.08
Net Current Asset Value -0.52
Tangible Book 0.64
Projected FCF -4.56
Median P/S Value 18.33
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt 1.05
Equity-to-Asset 0.51
Debt-to-Equity 0.59
Debt-to-EBITDA -0.43
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.01
DISTRESS
GREY
SAFE
Beneish M-Score -5.08
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -92.57%
WACC 14.6%

Profitability & Growth : 5/10

Current vs industry vs history
Operating Margin % -267.71
Net Margin % -306.62
ROE % -99.49
ROA % -59.23
ROC (Joel Greenblatt) % -491.78
3-Year Total Revenue Growth Rate -2.60
3-Year Total EBITDA Growth Rate -93.80
3-Year EPS w/o NRI Growth Rate -72.90
N/A

» XON's 30-Y Financials

Financials (Next Earnings Date: 2019-05-10)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XON

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare ROCO:4147 NAS:DNLI LSE:GNS XMCE:ALM SZSE:300294 NAS:PTLA XKRX:006280 NAS:AKCA NAS:CORT SZSE:002287 SZSE:002653 NAS:SGMO NAS:ESPR NAS:RXDX NAS:GBT NAS:MYOK NAS:XLRN TSE:4974 NAS:EDIT XKRX:095700
Traded in other countries I5X.Germany
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Intrexon is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Ratios

Current vs industry vs history
PB Ratio 1.47
PS Ratio 3.21
EV-to-EBIT -1.25
EV-to-EBITDA -1.35
EV-to-Revenue 4.03
Current Ratio 4.64
Quick Ratio 4.29
Days Inventory 116.01
Days Sales Outstanding 46.96
Days Payable 77.40

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -3.50

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.42
Price-to-Median-PS-Value 0.22
Earnings Yield (Joel Greenblatt) % -79.03

More Statistics

Revenue (TTM) (Mil) $ 164.75
EPS (TTM) $ -3.9
Beta 2.18
Volatility % 68.05
52-Week Range $ 3.95 - 19.94
Shares Outstanding (Mil) 160.62

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N